home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Combating Anthrax

  October, 8 2001 2:07
your information resource in human molecular genetics
Anthrax is a deadly disease that could potentially be used in biological terrorism or warfare. The bacterium that causes anthrax produces a toxin that is extremely deadly, causing a disease that is invariably fatal if not treated immediately with antibiotics. Now, a group of researchers led by John Collier and George Whitesides may have come up with a means of combating the toxin (Nature Biotechnology, Vol. 19, No. 10, 01 Oct 2001). They have designed a polyvalent inhibitor (PVI) of the toxin that protects rats for at least one week after receiving doses of toxin 10-times the minimum lethal amount. Rats exposed to the toxin in the absence of PVI normally survive for only a few hours.

Using their knowledge that the anthrax bacterium secretes three nontoxic proteins that assemble into toxin complexes on mammalian cell membranes, Collier and his team screened peptide libraries for an inhibitor that prevents the toxin assembly process. Their screen identified a 12-amino acid peptide that inhibited assembly, albeit weakly. They then set about creating a PVI by covalently linking multiple copies of this inhibitor to a flexible polyacrylamide backbone, increasing the inhibitory activity of the peptide by about 7,500-fold.

Their method of developing synthetic, polymeric, polyvalent inhibitors of protein - protein interactions may also turn out to be a useful tool for increasing the therapeutic potency of drugs such as antitumor peptides, growth factor receptor agonists, or molecules with related mechanisms of action.

R. John Collier
Department of Microbiology and Molecular Genetics
Harvard Medical School
200 Longwood Avenue
Boston, MA 02115
Email: jcollier@hms.harvard.edu

(C) Nature Biotechnology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.